801 top medical experts on Stomach Neoplasms across 48 countries and 31 U.S. states, including 669 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Stomach Neoplasms: Tumors or cancer of the stomach.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Gastrointestinal Neoplasms (4,266), Stomach Diseases (1,428).
  4. Clinical Trials ClinicalTrials.gov : at least 1,860 including 78 Active, 687 Completed, 417 Recruiting
  5. Synonyms: Cancer of Stomach,  Gastric Cancer,  Gastric Neoplasms,  Stomach Cancer


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Bang, Yung-Jue   ClinicalTrials.gov Google Publications
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma; Esophageal Neoplasms; Receptor, ErbB-2; Antibodies, Monoclonal, Humanized
    Categories: Drug Therapy; Therapeutic Use; Genetics; Administration & Dosage; Metabolism; Pharmacology
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)

  2. Chung, Hyun Cheol   ClinicalTrials.gov Google Publications
    Division of Medical Oncology, Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Review 
    Subjects: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Antibodies, Monoclonal, Humanized; Antineoplastic Agents
    Categories: Drug Therapy; Therapeutic Use; Genetics; Pathology; Metabolism; Administration & Dosage
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017)

  3. Ajani, Jaffer A   Medical Oncology   ClinicalTrials.gov Google Publications
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 18 biomedical companies, totalling $34,655, including $9,607.5 from  E.R. Squibb & Sons, L.L.C.
    Subjects: Adenocarcinoma; Esophageal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Gastrectomy
    Categories: Drug Therapy; Pathology; Therapy; Genetics; Therapeutic Use; Mortality
    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. (2021)
    Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (2014)

  4. Hyung, Woo Jin     Google Publications
    Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Gastrectomy; Adenocarcinoma; Laparoscopy; Lymph Node Excision; Robotic Surgical Procedures
    Categories: Surgery; Methods; Pathology; Mortality; Adverse Effects; Genetics
    Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). (2016)
    Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. (2019)

  5. Shitara, Kohei   ClinicalTrials.gov Google Publications
    Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Esophageal Neoplasms; Antineoplastic Agents
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Pathology; Genetics; Mortality
    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. (2021)
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)

  6. Ohtsu, Atsushi   ClinicalTrials.gov Google Publications
    Oita University Faculty of Medicine, Yufu City, Oita, Japan.
    Scientist  Highly Cited  Clinical Trial 
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma; Esophageal Neoplasms; Receptor, ErbB-2; Esophagogastric Junction
    Categories: Drug Therapy; Therapeutic Use; Metabolism; Administration & Dosage; Pathology; Mortality
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)

  7. Kang, Yoon-Koo     ClinicalTrials.gov Google Publications
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma; Esophagogastric Junction; Antineoplastic Agents; Esophageal Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Pathology; Genetics; Administration & Dosage; Metabolism
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017)

  8. Yang, Han Kwang     Google Publications
    Department of Surgery, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Gastrectomy; Adenocarcinoma; Laparoscopy; Biomarkers, Tumor; Postoperative Complications
    Categories: Surgery; Methods; Genetics; Pathology; Metabolism; Mortality
    Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (2012)
    Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). (2016)

  9. Lordick, Florian     ClinicalTrials.gov Google Publications
    University Cancer Center Leipzig UCCL, University Leipzig Medical Center, 04103, Leipzig, Germany.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Esophageal Neoplasms; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Neoadjuvant Therapy
    Categories: Drug Therapy; Therapy; Therapeutic Use; Pathology; Genetics; Methods
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Gastric cancer. (2020)

  10. Van, Cutsem Eric   Google Publications
    Division Head of Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
    Scientist  Highly Cited  Clinical Trial  Case Reports 
    Subjects: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal, Humanized; Esophagogastric Junction; Esophageal Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Therapy; Metabolism; Genetics
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (2010)
    Gastric cancer. (2016)

  11. Fuchs, Charles S   Medical Oncology   ClinicalTrials.gov Google Publications
    Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
    Physician  Highly Cited  Guideline  Clinical Trial 
    Disclosed payments from biomedical company (Merge Healthcare Incorporated) in 2021 for $54.89
    Subjects: Adenocarcinoma; Esophageal Neoplasms; Esophagogastric Junction; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapeutic Use; Therapy; Pathology; Administration & Dosage; Diagnosis
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)
    Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. (2014)

  12. Yoshikawa, Takaki   Google Publications
    Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Gastrectomy; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Oxonic Acid; Tegafur
    Categories: Therapeutic Use; Surgery; Drug Therapy; Pathology; Methods; Therapy
    Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017)
    Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. (2020)

  13. Noh, Sung Hoon   Google Publications
    Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Adenocarcinoma; Gastrectomy; Carcinoma, Signet Ring Cell; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Recurrence, Local
    Categories: Surgery; Pathology; Methods; Genetics; Mortality; Drug Therapy
    Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (2012)
    Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. (2014)

  14. Muro, Kei   Google Publications
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma; Esophageal Neoplasms; Peritoneal Neoplasms; Antibodies, Monoclonal, Humanized
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Mortality; Pathology; Genetics
    Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017)
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)

  15. Shah, Manish A   Medical Oncology   ClinicalTrials.gov Google Publications
    Medicine, Weill Cornell Medicine, New York, New York, USA .
    Physician  Highly Cited  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 24 biomedical companies, totalling $50,545.15, including $29,000 from  Merck Sharp & Dohme Corporation
    Subjects: Adenocarcinoma; Esophageal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Antibodies, Monoclonal, Humanized
    Categories: Drug Therapy; Therapeutic Use; Genetics; Pathology; Metabolism; Administration & Dosage
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (2018)
    Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. (2011)

  16. Lee, Jeeyun   ClinicalTrials.gov Google Publications
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Receptor, ErbB-2; Antineoplastic Agents
    Categories: Genetics; Drug Therapy; Pathology; Therapeutic Use; Metabolism; Methods
    Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. (2015)
    Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. (2018)

  17. Kim, Hyung Hun     ClinicalTrials.gov Google Publications
    Department of Surgery, Seoul National University Bundang Hospital, Seoul, Korea.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Gastrectomy; Laparoscopy; Adenocarcinoma; Biomarkers, Tumor; Lymph Node Excision
    Categories: Surgery; Methods; Pathology; Genetics; Adverse Effects; Metabolism
    Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). (2016)
    Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. (2019)

  18. Sasako, Mitsuru   ClinicalTrials.gov Google Publications
    Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Gastrectomy; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Lymph Node Excision
    Categories: Surgery; Drug Therapy; Therapeutic Use; Methods; Mortality; Genetics
    Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. (2010)
    Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. (2011)

  19. Ji, Jia-fu     Google Publications
    Gastrointestinal Cancer Center, Beijing University Cancer Hospital, Beijing, China.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Adenocarcinoma; Gastrectomy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Laparoscopy
    Categories: Genetics; Metabolism; Pathology; Methods; Surgery; Drug Therapy
    Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (2012)
    Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. (2019)

  20. Kim, Kyoung Min   Google Publications
    Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Adenocarcinoma; Biomarkers, Tumor; Carcinoma; Gastric Mucosa; Antineoplastic Combined Chemotherapy Protocols
    Categories: Genetics; Pathology; Metabolism; Methods; Diagnosis; Immunology
    Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. (2015)
    Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. (2018)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);